top of page
Mesa Arch.jpg
Formation Venture Engineering Logo Web R

Portfolio

Akston Biosciences Logo.png

Akston Biosciences

AKSTON BIOSCIENCES

LEARN MORE

LeviSense Medical

Levisense Logo.png

LEVISENSE MEDICAL

LEARN MORE

NonExomics

Nonexomics Logo.jpg

NONEXOMICS

LEARN MORE

Cell IDx

Cell IDx Logo.png

CELL IDX

LEARN MORE

NeuroDex

Neurodex Logo.jpg

NEURODEX

LEARN MORE

Adeptrix

Adeptrix Logo.png

ADEPTRIX

LEARN MORE

TriBiotica

Tribiotica Logo.png

TRIBIOTICA

LEARN MORE

Akston Biosciences Logo.png
About

Akston Biosciences is building upon its Fc-fusion drug platform to develop market-share-
cornering new drugs and vaccines. Entering phase 3 clinical development in the EU and
India is AKS-452, a potentially universal pandemic-ending COVID vaccine suitable for use
the world over. Next year the company will begin clinical and business development of
its human diabetes products, which include a possible cure for Type I Diabetes in
children, and a market transforming smart, once-weekly insulin for Type 1 & 2 diabetics.
The ultra-long-lasting insulins are already licensed for veterinary applications and are in
later stages of clinical development in dogs and cats.

Founder
Levisense Logo.png
About

Levisense is creating and commercializing revolutionary medical beds that sense and
control pressure and air flow for the prevention and treatment of bed sores. This new
medical mattress technology that is expected to transform the high-end medical
bedding market. The LeviSense SensorCell technology interrogates and controls the
patient-bed interface to prevent bed sores from forming, or to heal existing bed sores.

Founder
Nonexomics Logo.jpg
About

NonExomics is a computational biology-driven discoverer of nonexomic causes,
treatments and cures for hundreds of rare and inherited diseases and numerous
cancers. The nonexomic region of the human genome is barren of conventional genes
and therefore has been believed to not be contributing to disease. NonExomics
researchers discovered that mutations within this region are leading to the manufacture
of proteins that appear to be causing or enhancing a host of rare and inherited diseases
and cancers. These newly discovered proteins have never been drugged, and they may
explain why a host of genetic disorders are incurable or of unknown etiology.

Founder
About
Cell IDx Logo.png

Cell IDx’s primary business is focused on the discovery and commercialization of
biological and organic tools for the life science research and clinical diagnostic markets.
Their initial entrants have been kits and reagents for the pathology slide-staining
market. The kits are superior to current competitors in terms of performance, speed,
and ease of use.

Founder
Neurodex Logo.jpg
About

NeuroDex accurately detects neurological diseases and provides monitoring through
simple blood assays. Displaces painful cerebral spinal taps and brain biopsies. It has
developed and is commercializing a technology to rapidly extract neurologically-derived
exosomes from blood. Exosomes are made in large numbers by all human cells on a
daily basis. Diseased cells emit exosomes that carry the signature of their disease. Thus,
nearly all neurological diseases and disorders can be diagnosed and potentially treated
or cured by leveraging the NeuroDex technology. This new approach is rapidly being
adopted by pharma companies for clinical trials.

Founder
Adeptrix Logo.png
About

Adeptrix is commercializing a new technology for protein mass spectrometry called
BAMS. Its consumable kits and reagents enhance the amount of information coming
from targeted proteomics - enabling the development of high fidelity biomarkers.

Founder
Tribiotica Logo.png
About

TriBiotica is creating new tumor surface markers for immunotherapy. It is developing a
new immunotherapy based on molecules called Haplomers. The Haplomers have been
shown in culture to paint the surface of tumor cells with novel immunotherapy drug
targets.

Founder
bottom of page